Physician profile
Mohammad A Khalid
NPI 1972525897
$2,901.09
in general payments reported to CMS, 2019-2025
23 companies · $40.95 in 2025
The $40.95 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $751 · 2021: $682 · 2022: $420 · 2023: $252 · 2024: $62.04 · 2025: $40.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $354.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $588.78 | 2019-2022 | |
| Glaxosmithkline, LLC. | $406.34 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Allergan, INC. | $285.62 | 2019-2020 | |
| Abbvie INC. | $270.17 | 2021-2023 | |
| Novo Nordisk INC | $211.76 | 2019-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $204.57 | 2019-2023 | Emgality, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.73 | 2019-2021 | |
| Gilead Sciences, INC. | $182.13 | 2019-2021 | |
| Zimmer Biomet Holdings, INC. | $108.27 | 2019 | |
| Pfizer INC. | $97.00 | 2019-2024 | |
| Abbott Laboratories | $61.67 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $49.15 | 2019-2020 | |
| Biogen, INC. | $36.79 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.10 | 2020 | |
| Paratek Pharmaceuticals, INC. | $32.49 | 2021-2025 | Nuzyra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $20.30 | 2020 | |
| Exact Sciences Corporation | $19.68 | 2023 | Cologuard Collection Kit |
| Organogenesis INC. | $18.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.77 | 2019 | |
| Kerecis Limited | $13.82 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.32 | 2022 | |
| Eisai INC. | $13.05 | 2021 | |
| Daiichi Sankyo INC. | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.